Skip to Content
Merck
CN

Bromoderma in a patient with migrating partial seizures in infancy.

Epilepsy research (2010-08-03)
Shin Nabatame, Yoshiaki Saito, Hiroshi Sakuma, Hirofumi Komaki, Eiji Nakagawa, Kenji Sugai, Masayuki Sasaki, Kentaro Uchiyama, Maki Kosaka
ABSTRACT

A 5-month-old boy with migrating partial seizures in infancy acquired bromoderma 4 weeks after initiating potassium bromide (KBr) therapy (60mg/kg/day). Erythematous pustules appeared on the forehead within a few days of attaching electroencephalography electrodes, and on the cheek at the site of nasogastric tube fixation. These later developed into vegetant plaques. Bromoderma aggravated at the site of skin biopsy that was performed 4 weeks after KBr termination. Bromoderma tuberosum should be recognized widely, considering the increasing use of KBr for treating intractable childhood epilepsy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Potassium bromide, BioXtra, ≥99.0%
Sigma-Aldrich
Potassium bromide, anhydrous, powder, 99.95% trace metals basis
Sigma-Aldrich
Potassium bromide, anhydrous, powder, 99.999% trace metals basis
Sigma-Aldrich
Potassium bromide, BioUltra, ≥99.5% (AT)
Sigma-Aldrich
Potassium bromide, ACS reagent, ≥99.0%
Sigma-Aldrich
Potassium bromide, ≥99% trace metals basis
Sigma-Aldrich
Potassium bromide, ReagentPlus®, ≥99.0%